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Abstract
Dengue is an emerging infectious disease that has become the most important arboviral infection worldwide. There are four
serotypes of dengue virus, DENV-1, DENV-2, DENV-3, and DENV-4, each capable of causing the full spectrum of disease.
rDEN1D30 is a live attenuated investigational vaccine for the prevention of DENV-1 illness and is also a component of an
investigational tetravalent DENV vaccine currently in Phase I evaluation. A single subcutaneous dose of rDEN1D30 was
previously shown to be safe and immunogenic in healthy adults. In the current randomized placebo-controlled trial, 60
healthy flavivirus-naive adults were randomized to receive 2 doses of rDEN1D30 (N=50) or placebo (N=10), either on study
days 0 and 120 (cohort 1) or 0 and 180 (cohort 2). We sought to evaluate the safety and immunogenicity of this candidate
vaccine in 50 additional vaccinees and to test whether the humoral immune response could be boosted by a second dose
administered 4 or 6 months after the first dose. The first dose of vaccine was well tolerated, infected 47/50 vaccinees and
induced seroconversion in 46/50 vaccinees. Irrespective of dosing interval, the second dose of vaccine was also well
tolerated but did not induce any detectable viremia or $4-fold rise in serum neutralizing antibody titer.Only five subjects
had an anamnestic antibody response detectable by ELISA following a second dose of vaccine, demonstrating that the
vaccine induced sterilizing humoral immunity in most vaccinees for at least six months following primary vaccination.The
promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue
vaccine.
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Introduction
Dengue fever has emerged as the world’s most important
mosquito-borne viral disease. Four antigenically distinct serotypes
of dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4) are
transmitted by Aedes aegypti and Ae. albopictus mosquitoes, and the
geographical spread of both mosquito vectors and the four viruses
has led to an increased number of countries experiencing epidemic
dengue fever [1]. In dengue endemic countries, hyperendemicity
in many urban centers as well as focal outbreaks in rural areas are
a major public health concern [2,3]. Up to 3 billion people are at
risk of infection in tropical and sub-tropical countries, and an
estimated 50 – 100 million people develop dengue illness annually
[1,4,5]. Although most dengue-infected individuals are treated on
an outpatient basis, hundreds of thousands of hospitalizations and
approximately 20,000 deaths per year are attributable to dengue.
In many countries, children bear much of this disease burden [6].
The spectrum of DENV disease ranges from subclinical disease
or undifferentiated febrile illness to classic dengue fever (DF) and
to life-threatening dengue hemorrhagic fever/dengue shock
syndrome (DHF/DSS). All four DENV serotypes are capable of
causing the full spectrum of disease, although differences in
virulence might exist [4,7,8]. Long-term homotypic immunity is
induced by a single infection with DENV [9]; however,
heterotypic protection is less durable [10], and pre-existing
immunity to one DENV serotype has been identified as a risk
factor for more severe disease upon secondary, heterotypic
infection [8,11,12,13]. Therefore, a DENV vaccine needs to
induce long-lived protective immunity against all four DENV
serotypes. In order to do so, more than one dose of a live
attenuated tetravalent vaccine may be needed [14,15,16,17,18,
19,20]. For example, two doses of the Mahidol/US Army/Pasteur
PDK passaged tetravalent vaccine, given 180 days apart, were
needed to achieve greater than 75% seroconversion against 3 or
more serotypes [15]. Similarly, three dose of ChimeriVax are
needed to induce a trivalent or tetravalent response in .80% of
flavivirus-naive children and adults [14].
In preparation for tetravalent DENV vaccine studies, others
have conducted two dose studies to evaluate the safety, infectivity
and immunogenicity of a second dose of monovalent DENV
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neutralization test (PRNT50) seroconversion rates between 46%
and 100% following the first dose of their live attenuated
monovalent DENV vaccines and limited seroconversion following
a second dose given one or three months later [17].
The Laboratory of Infectious Diseases (LID) at the NIH has
developed monovalent vaccines against all four DENV serotypes
using a variety of strategies [21,22,23,24,25,26].The NIH
monovalent DENV-1-4 vaccines were found to be safe, highly
attenuated, and immunogenic in healthy adult volunteers when
given as a single dose of 10
3 plaque-forming units (PFU)
[22,23,24]. Dengue-like illness was not observed in the more than
500 vaccinees evaluated thus far, and vaccine-related serious
adverse events (SAEs) did not occur. The most common
reactogenicity events were an asymptomatic faint maculopapular
rash over the trunk and proximal extremities and a transient
neutropenia that lasted 2–3 days without associated clinical signs.
Specifically, the rDEN1D30 vaccine, when evaluated as a single
dose of 10
3 PFU administered subcutaneously, caused low-level
viremia (10 PFU/mL) in 9/20 vaccinees, starting around day 10
and lasting for approximately three days [22]. None of the
volunteers developed a dengue-like illness, nor did any report
vaccine-related reactogenicity that interfered with daily activities.
Compared to placebo recipients, a significant increase in the
occurrence of any solicited clinical sign or laboratory finding other
than asymptomatic rash and neutropenia, was not observed in
vaccinees. The vaccine induced a four-fold or greater rise in
PRNT60 antibody titers in 95% of the vaccinees [22].
Here we present the results of a two-dose study of the
monovalent rDEN1D30 vaccine in healthy adult volunteers. This
study was designed to evaluate the safety and immunogenicity of a
new lot of rDEN1D30 in 50 vaccinees in preparation for
tetravalent vaccine trials and to determine a suitable interval for
administration of a second dose of vaccine. The 4-month dosing
interval was chosen because evaluation of tetravalent dengue
vaccine formulations containing rDEN1D30 demonstrated that
neutralizing antibody responses in rhesus macaques could be
boosted with a second dose of vaccine given at 4 months (but not
at 1 month) post dose one [10,27]. The 6-month interval was
chosen because clinical trials with ChimeriVax indicated that
boosting at an interval longer than 4 months was preferable [14].
Two cohorts of 30 subjects were recruited to receive two doses of
the rDEN1D30 vaccine or placebo with the second dose given
either on Day 120 or on Day 180 after dose 1. While the first dose
of DEN1D30 was safe, infectious, and immunogenic in 92% of the
vaccinees, the second dose of the vaccine, given at either interval,
did not cause detectable viremia and did not boost neutralizing
antibody titers, indicating that a single dose of monovalent
DEN1D30 vaccine induced sterilizing humoral immunity against a
second dose of this vaccine for at least 6 months.
Methods
Ethics Statement
The study was performed under a NIAID-held investigational
new drug application (BB-IND #11677) reviewed by the US Food
and Drug Administration. The clinical protocol, consent form, and
Investigators’ Brochure were developed by Center for Immuniza-
tion Research and National Institute of Allergy and Infectious
Diseases (NIAID) investigators and were reviewed and approved
by the NIAID Regulatory Compliance and Human Subjects
Protection Branch (RCHSPB), the NIAID Data Safety Monitoring
Board (DSMB), the Western Institutional Review Board (WIRB),
and the Johns Hopkins University Institutional Biosafety Com-
mittee. Written informed consent was obtained from each
volunteer in accordance with the Code of Federal Regulations
(21 CFR 50) and International Conference on Harmonisation
guidelines for Good Clinical Practice (ICH E6). The DSMB of the
NIAID Division of Clinical Research reviewed all safety data at 6-
month intervals.
Trial Design and Study Setting
This single-institution parallel group Phase 1 trial was
conducted as a randomized double-blind placebo-controlled study
at the Center for Immunization Research (CIR) at the Johns
Hopkins Bloomberg School of Public Health (JHSPH). Study
subjects were enrolled between May 2007 and July 2008 under
study protocol CIR-229, registered at ClinicalTrials.gov as Study
NCT00473135. The study was designed to evaluate the safety of
two doses of the rDEN1D30 vaccine, given at day 0 and again at
day 120 or day 180, and to evaluate the virologic and serologic
response to the vaccine after dose 1 and dose 2. Viremia was
characterized by mean peak titer, day of onset, and duration. The
serologic response was characterized by PRNT60 at study day 28
and 42 following both first and second vaccination.
Two cohorts were evaluated; cohort 1 subjects received vaccine
or placebo at study day 0 and again at study day 120, subjects in
cohort 2 received vaccine or placebo at study day 0 and again at
study day 180. Within each cohort, subjects were randomized such
that 25 would receive vaccine and 5 would receive placebo. A
sample size of 25 vaccinees and 5 placebo recipients in each cohort
was chosen based on our previous Phase I trial of this candidate
DENV-1 vaccine [22] and to expand the safety evaluation of this
vaccine. Subjects were randomized using a random number
generator, by a member of the CIR who was not involved in the
clinical or laboratory evaluation of the subjects. Subjects who had
been enrolled could be replaced until study day 42 following first
vaccination if they did not complete study day 28 or study day 42,
or if their specimens were not usable in the immunological
assessment at study day 42 due to protocol-defined reasons. If a
volunteer was replaced, the safety data and viremia data for that
subject, up to the point of replacement, were included in the
Author Summary
Globally, dengue fever has become the most common
clinically significant mosquito-transmitted viral illness.
Dengue viruses exist as four serotypes, and increasingly
several serotypes co-circulate in the same region. Infection
with one serotype increases the risk of severe illness
following infection with a second serotype. Therefore, any
dengue virus vaccine needs to protect against all four
serotypes. We and others are working to develop a live-
attenuated tetravalent dengue vaccine that contains four
monovalent vaccine viruses. Since two or more doses of
such a vaccine are thought to be necessary for induction
of long-lasting protective immunity, a feasible dose
interval needs to be determined. Here, boosting with a
second dose of a monovalent dengue type 1 (DENV-1)
vaccine at four months or six months was compared in
flavivirus-naı ¨ve healthy adult subjects with regard to
safety, infectivity, and immunogenicity. We found that
both doses of the vaccine were safe and well tolerated.
While the first dose infected 92% of recipients, the second
dose was neither infectious nor immunogenic, irrespective
of the dose interval. These findings indicate that in most
subjects, a single dose of this monovalent vaccine confers
sterilizing humoral immunity against a second dose for at
least six months.
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subject they replaced and the treatment assignment remained
blinded.
Study Population
Healthy adult male and non-pregnant female volunteers were
recruited from the Baltimore, Maryland and Washington DC
metropolitan areas. Written informed consent was obtained from
each volunteer in accordance with the Code of Federal Regulations
(21 CFR 50) and International Conference on Harmonisation
guidelines for Good Clinical Practice (ICH E6). Healthy volunteers
18 to 50 years of age were enrolled if they met the following
eligibility criteria: normal findings during physical examination;
negative for antibodies to all DENV serotypes, yellow fever virus,
West Nile virus, St. Louis encephalitis virus; negative for hepatitis B
and C; negative for HIV; normal values for complete blood count
(CBC) with differential, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), creatinine, coagulation studies, and
urinalysis. Additional safety-related exclusion criteria were also
applied. Female volunteers were required to have a negative result
on a urine pregnancy test at screening and on each vaccination day
and were required to use a reliable method of contraception.
Clinical Procedures and Evaluation
On study day 0, volunteers reported to the CIR outpatient clinic
and were randomly assigned to receive either vaccine or placebo
(vaccine diluent) given as a 0.5 mL subcutaneous injection. The
appearance of the vaccine and placebo was identical. All study
staff involved in the clinical and laboratory assessment of the
subjects remained blinded to the treatment assignment until the
study was unblinded at study day 42 following the second
vaccination. Subjects were monitored for immediate adverse
reactions for at least 30 minutes after vaccination. Each subject
was given a digital thermometer and a diary card to record his/her
oral temperature three times per day for 16 days. Clinical
assessments were performed every other day through study day 16
and again on study days 21, 28 and 42 post-vaccination. During
clinical visits, a medical provider performed a focused physical
examination to evaluate for local reactogenicity (pain, erythema
and swelling at the injection site) and systemic reactogenicity
(lymphadenopathy, photophobia, rash, and hepatomegaly) and
questioned subjects specifically about dengue-related symptoms
(fever, headache, retro-orbital pain, nausea, photophobia, fatigue,
myalgia, arthralgia, and rash). These signs and symptoms as well
as the specific clinical laboratory studies described below were
classified as solicited reactogenicity. In addition, subjects were
questioned at each visit about other intercurrent illnesses. For each
dose, blood was drawn at each assessment for detection of viremia
through study day 16 post-vaccination and for antibody assay on
study days 0, 28 and 42 post-vaccination. Prior to vaccination,
baseline CBC with differential, ALT and/or AST and coagulation
studies were obtained. After each vaccination, a CBC with
differential was obtained every other day through study day 16.
Coagulation studies were done every fourth day through study day
16 post-vaccination and again at day 28 post-vaccination. Serum
for ALT testing was collected every other day from study day 4
through day 16 and again on study day 21 post-vaccination.
Subjects returned to the clinic at study day 90 (cohort 1) or study
day 150 (cohort 2) for repeat HIV, hepatitis B and hepatitis C
testing and to assess for continued eligibility for second
vaccination. Exclusion criteria for second vaccination included
positive HIV-1 serology, active hepatitis B or hepatitis C infection,
pregnancy, receipt of a live vaccine within 4 weeks prior to second
vaccination or a killed vaccine within 2 weeks prior to second
vaccination, use of immunosuppressive doses of corticosteroids
(excluding topical or nasal) or immunosuppressive drugs within 30
days prior to second vaccination, receipt of an investigational
agent in the 30 days prior to second vaccination, or history of
severe allergic reaction or anaphylaxis associated with first
vaccination. Clinical and laboratory assessments following the
second vaccination were identical to the first vaccination
throughout the 42-day follow-up period. All adverse events were
graded for intensity and relationship to vaccine. Fever was
determined by oral temperature recorded on two consecutive
measurements 1 hour or more apart and was defined as grade 1
(38.0uC–38.6uC), grade 2 (38.7uC–39.1uC), or grade 3 (.39.1uC).
Adverse Events
Adverse events were graded as mild (no effect on daily activity),
moderate (required an intervention or interfered with daily activity),
or severe (prevented daily activity). Abnormal hematology,
coagulation and serum chemistry findings were also graded as
mild, moderate, or severe, using standardized toxicity tables. A
dengue-like syndrome was defined as infection associated with fever
and $ 2 of the following symptoms: Grade 2 headache lasting
12 hours, Grade 2 photophobia lasting $12 hours, Grade 2
generalized myalgia lasting $12 hours. Grade 2 retro-orbital pain
lasting $12 hours, or sustained or intermittent epistaxis lasting
$24 hours. Dengue infection was defined as recovery of vaccine
virus from the blood and/or seroconversion to DENV-1 as
measured by 60% plaque-reduction neutralization titer (PRNT60).
All adverse events and abnormal clinical findings were collected for
the duration of the study and were followed to resolution. Serious
adverse events were defined in accordance with 21 CFR312,32.
Vaccine
rDEN1D30 is a recombinant, live attenuated virus derived from
the DENV-1 Western Pacific (WP) wild-type virus by deletion of
30 nucleotides in the 39 UTR [28]. The vaccine virus in the
current clinical lot of this investigational vaccine (Lot
DEN1#104A, Charles River Laboratories, Malvern PA) is
identical at the amino acid level to that evaluated in an earlier
phase I study (Lot DEN1#1) [22]. A cDNA clone was generated
to match the sequence of the previously manufactured rDEN1D30
(LotDEN1#1) and vaccine virus was derived and manufactured in
qualified Vero cells. The genome sequence of the vaccine virus in
Lot DEN1#104A differed from that of Lot DEN1#1 at seven
nucleotide positions, however all substitutions were translationally
silent. Vaccine virus was stored at -80615uC until use. Just prior
to vaccination, vaccine virus was removed from the freezer and
diluted to a concentration of 3.3 log10 PFU/mL with vaccine
diluent (1X Leibovitz L-15 medium lacking phenol red). L-15 was
also used as the placebo. The 1X Leibovitz L-15 medium was
prepared from a qualified lot of 2X Leibovitz L-15 (Lonza,
Walkersville, MD) mixed 1:1 with sterile water for injection.
Diluted vaccine was administered as a 0.5 mL subcutaneous
injection within four hours of removal from the freezer . The virus
titer of the diluted and undiluted vaccine was determined to
confirm the potency of the vaccine.
Virus quantitation and serologic assessment
Virus titers were determined by plaque assay after inoculation of
undiluted or serial 10-fold dilutions of serum onto Vero cell
monolayer cultures, as described previously [21]. The lower limit
of virus detection in this assay is 0.5 PFU/mL. Antibody responses
to DENV-1 virus were determined by PRNT60 as described
previously [21], using DENV-1 (WP) as the target virus in the
assay. For comparison of the PRNT60 values induced by the
A Single Dose of rDEN1D30 Is Strongly Immunogenic
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previous clinical trial of rDEN1D30 were assayed in parallel with
those collected during this trial. Seroconversion was defined as a
$4-fold rise in serum neutralizing antibody to wild-type DENV-1
by study day 42 following each vaccination. Following first
vaccination, this corresponded to a PRNT60 of $1:20 as all
subjects were flavivirus naı ¨ve (PRNT60,1:5). Following second
vaccination, the titer obtained on day 42 post-second vaccination
(day 162 or day 222) was compared with the titer from Study Day
120 or Study Day 180. An IgG ELISA against whole virus was
used to detect the presence of non-neutralizing antibody against
DENV-1 (WP) virus.
Data analysis
The present study is largely descriptive. Comparisons of the
incidence of solicited adverse events between groups, neutrophil
count parameters (baseline, absolute and relative decline, day of
nadir) between groups, and comparisons of the ages of vaccinees
and placebo recipients were performed using a 2-tailed Fisher
Exact Test. Comparisons of mean peak titer, onset of viremia,
duration of viremia, were performed using Tukey-Kramer HSD
test. Mean values 6 standard error (SE) are indicated. Statistical
analysis was performed using JMP software (version 5.0.1.2; SAS
Institute).
Results
Enrollment
A total of 145 subjects were screened and 62 subjects were
enrolled in the trial (Figure 1). All subjects who received vaccine
(or placebo) were included in the safety assessment even if they did
not complete day 42 and were replaced. Two subjects were
replaced; one had received vaccine and the other had received
placebo. Fifty-one subjects received the first dose of vaccine (26 in
cohort 1 and 25 in cohort 2) and 11 subjects received the first dose
of placebo (6 in cohort 1 and 5 in cohort 2). Forty-six subjects (23
in each cohort) received a second vaccination and 10 subjects
received placebo (5 in each cohort) at second vaccination; all were
included in the safety assessment. One vaccinee in cohort 1
withdrew prior to study day 222 and was not included in the
immunological assessment (Figure 1). A statistically significant
difference in age was neither observed between vaccinees (3261.4
years) and placebo recipients (3662.5 years), nor between the two
cohorts (data not shown). Twenty-six subjects (42%) were female
and 36 subjects (58%) were male. This difference was not
significant. Thirty-one of 51 vaccinees (61%) self-reported as
Black, 17 (33%) as White, and the remaining 6% were comprised
of multi-racial, Pacific Islander, or unknown racial identity. In
comparison, 9/11 placebo recipients (82%) self-reported as Black
and the remaining 18% self-reported as White.
Adverse events following Dose 1
The type and frequency of adverse events reported by subjects
who received this new lot of rDEN1D30 (Lot DEN1#104A) were
compared with those reported by subjects who received the Lot
DEN1#1 to establish bioequivalence and to expand our safety
database. Two SAEs occurred following dose 1 in a single vaccine-
recipient. This subject fractured his ankle and, while hospitalized
for surgical repair of the ankle fracture (SAE #1), had surgical
repair of a pre-existing spinal stenosis (SAE #2). Both SAEs were
judged to be unrelated to vaccination. The vaccine was well
tolerated by all vaccinated subjects. None of the subjects developed
a dengue-like illness. One vaccinee developed mild injection site
erythema starting 4 days post-vaccination and lasting for 4 days.
None of the other subjects developed injection site erythema,
induration, or tenderness during the intensive follow-up period (16
days post-vaccination). The frequency and severity of solicited
reactogenicity events following vaccination with rDEN1D30, Lot
DEN1#104A, was comparable to that reported following
vaccination with the previous lot, DEN1#1[22], and selected
reactogenicity events are shown in Table 1.
Overall, 42/51 subjects (82%) who received rDEN1D30, Lot
DEN1#104A developed at least one solicited clinical or
laboratory adverse event, compared with 5/11 placebo recipients
(45%), p=0.02. The most commonly observed adverse events
were rash, headache, and neutropenia. Since the frequencies of
adverse events were similar for cohort 1 and cohort 2 (shown
separately in Table 1), the pooled data is discussed here. The only
solicited adverse event that showed a trend towards more common
occurrence in vaccine recipients was rash (27% of vaccinees, 0%
placebo recipients, p=0.06). A mild asymptomatic maculopapular
rash, similar in character to what we have described previously,
was detected in 14 vaccinees (Table 1) [22,23,24]. The mean
onset of rash was study day 12.860.4 and the mean duration was
1162.2 days. Because the rash was not noticed by the majority of
the volunteers, the reported duration of rash may be longer than
its actual duration because subjects were not seen between study
days 21 and 28 and the rash was not determined to be resolved
until the subject was evaluated by a clinician at study day 28.
There were 39 episodes of headache reported by 21 vaccinees
throughout the 42-day post-vaccination period. The mean
duration of headache was 2.260.6 days with a mean day of onset
of 10.161.2. Sixty-nine percent of headache episodes were of mild
severity and 31% were of moderate severity. There were four
episodes of headache reported by 2 placebo recipients; this
difference was not statistically significant when compared with
vaccinees. Seven vaccinees (14%) reported mild (6 subjects) or
moderate (1 subject) retro-orbital pain following dose 1, six of
them between day 13 and 16. None of the subjects developed fever
during the 16-day follow-up. Four vaccinees reported myalgia that
was determined to be possibly, probably, or definitely related to
vaccine. Three vaccinees (6%) reported a mild myalgia lasting 3–5
days; one vaccinee reported moderate myalgia lasting 2 days. One
placebo recipient (9%) reported myalgia lasting 3 days.
Twenty-three of 51 vaccinees (45%) in the current study (Lot
DEN1#104A) developed transient neutropenia, similar to the
frequency observed in our previous study (Table 1). Neutropenia
in vaccinees was graded as mild (range 1,000–1,500/mm
3)i n1 5
subjects, moderate (range 750–999/mm
3) in 3 subjects , and
severe (range 500–749/mm
3) in 5 subjects. The onset of
neutropenia ranged from Study Day 4 to Study Day 16, [mean
day of onset =11.860.7 (SE)] and resolved in all subjects. The
mean duration of neutropenia in vaccinees was 2.4 days 60.3
days. Four of 5 subjects with severe neutropenia had an
ANC,750/mm
3 on a single day and one subject had an
ANC,750/mm
3 on days 12 and 14. Two of 11 placebo recipients
(18%) developed neutropenia, both episodes were mild. In the
current study, vaccinees who became neutropenic had a
statistically significant lower mean baseline ANC (2,663/mm
3)
than vaccinees who did not become neutropenic (3,855/mm
3),
a=0.01 (Table 2). Individuals who had a baseline ANC of
#3,000/mm
3 were more likely to become neutropenic than
individuals with baseline ANCs . 3,000/mm
3 (p,0.0001).
Sixteen of the 23 vaccinees (70%) who became neutropenic had
a baseline ANC of #3,000/mm
3 compared with 4/28 (14%)
vaccinees who did not become neutropenic. The mean absolute
decline in ANC was not significantly different between those
vaccinees who became neutropenic and those who remained non-
A Single Dose of rDEN1D30 Is Strongly Immunogenic
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doi:10.1371/journal.pntd.0001267.g001
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vaccinees was significantly greater than in placebo recipients
(Table 2). One vaccinee developed a moderate elevation in serum
ALT activity that was possibly related to vaccine. The ALT level
peaked on day 15 at 123 IU/L and was not associated with
nausea, vomiting, abdominal pain, or hepatomegaly. Although at
screening this subject denied taking any prescription drugs, she
later indicated that she had been taking anti-depressive medication
for several weeks, which may have contributed to the elevation in
serum ALT level.
Adverse events following Dose 2
Following Dose 2, none of the subjects developed dengue-like
illness, fever, retro-orbital pain, or rash (Table 1). A statistically
significant difference in the number of volunteers reporting
headache between vaccinees and placebo recipients was not
observed. The incidence of neutropenia following second
vaccination was similar in vaccine and placebo recipients; four
vaccine recipients (9%) developed mild neutropenia and one
placebo recipient (10%) developed moderate neutropenia. Two
vaccinees developed a mild transient elevation in serum ALT level
(peak of 82 IU/L on day 4 and peak of 83 IU/L on day 7 post
dose 2, respectively). The elevated ALT level in both subjects
resolved within 4 days. Neither of these subjects met the definition
of infection following second dose nor did they have any increase
in ELISA antibody titer following the second dose.
Assessment of viremia and DENV-1 antibody response
Thirty-four of 51 vaccinees (67%) who received rDEN1D30 Lot
DEN1#104A had detectable viremia following the first vaccina-
tion (Table 3). The percent of volunteers with viremia, the mean
peak virus titer, and the mean number of viremic days following
dose 1 in the current study were comparable to that observed in
the previous study rDEN1D30 Lot DEN1#1 [22]. Following dose
1, 94% vaccinees were infected with rDEN1D30 Lot
DEN1#104A (88% in cohort 1 and 100% in cohort 2) and
95% with rDEN1D30 LotDEN1#1. Amongst the 48 subjects
infected with rDEN1D30 Lot DEN1#104A, one was viremic on
day 12 but did not meet criteria for seroconversion, resulting in an
overall seroconversion rate of 92% to wild-type DENV-1 virus by
study day 42 (84% in cohort 1 and 100% in cohort 2, Table 4).
With regard to immunogenicity, PRNT60 titers against wild-type
DENV-1 induced by the two lots of vaccine were comparable (less
than a 2-fold difference) (Table 4).
Twenty-three vaccinees per cohort received a second dose of
vaccine (Figure 1). Following a second dose of vaccine at either
interval, viremia was not detected in any subject (Table 1), and
none of the subjects had a 4-fold or greater rise in serum
Table 1. Clinical and virology data from subjects vaccinated with rDEN1D30 or placebo.
No. subjects with indicated clinical sign/symptom (%)
Treatment
Cohort and dosing
schedule Dose # N
No.
viremic (%) Fever Rash Headache Neutropenia
1 qALT
2
DEN1D30 (DEN1#1)
3 Single dose 1 20 9 (43) 1
4 (5) 9 (40) 8 (40) 9
5 (45) 0 (0)
DEN1D30 (DEN1#104A) Cohort 1, 0+120 1 26 17 (65) 0 (0) 8 (31) 11 (42) 11 (42) 1 (4)
DEN1D30 (DEN1#104A) Cohort 2, 0+180 1 25 17 (68) 0 (0) 6 (24) 10 (40) 12 (48) 0 (0)
Placebo
6 Placebo 1 11 0 (0) 0 (0) 0 (0) 2 (18) 2 (18) 0 (0)
DEN1D30 (DEN1#104A) Cohort 1, 0+120 2 23 0 (0) 0 (0) 0 (0) 10 (43) 1 (4) 1 (4)
DEN1D30 (DEN1#104A) Cohort 2, 0+180 2 23 0 (0) 0 (0) 0 (0) 7 (30) 3 (13) 1 (4)
Placebo
7 Placebo 2 10 0 (0) 0 (0) 0 (0) 1(10) 1(10) 0 (0)
1Neutropenia is defined as an ANC #1500/mL.
2The upper limit of normal (ULN) for ALT is 54/mL (63/mL) for females (males). ALT.1.256ULN is recorded as elevated.
3Historical data [28].
4Fever was due to unrelated viral pharyngitis.
5In this previously reported study neutropenia was defined as ,1500/mL. Eight subjects were reported to be neutropenic. One additional subject had an ANC of 1500/
mL. This subject is included in the current analysis.
6Placebo recipients from only the first dose of the 2-dose study are presented.
7Placebo recipients from only the second dose of the 2-dose study are presented.
doi:10.1371/journal.pntd.0001267.t001
Table 2. Absolute neutrophil counts (ANC) in neutropenic rDEN1?30 vaccinees, non-neutropenic rDEN1D30 vaccinees, and
placebo recipients following a single dose of vaccine.
Group No. subjects
Baseline ANC
[Stat group]
1
Mean absolute decline in
neutrophils
[Stat group]
2
Mean % decline
[Stat group]
2
Mean day of ANC
nadir
[Stat group]
2
Vaccine (neutropenic) 23 2,663 [A] 1,594 [A] 56% [A] 14.360.8 [A]
Vaccine (non-neutropenic) 28 3,855 [B] 1,440 [A] 36% [B] 12.060.8 [AB]
Placebo 10 3,100 [AB] 501[B] 17% [C] 9.061.3 [B]
1Means not assigned the same letter are significantly different (a=0.01).
2Means not assigned the same letter are significantly different (a=0.05).
doi:10.1371/journal.pntd.0001267.t002
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of the subjects met the protocol definition of infection following a
second dose of rDEN1?30 (Table 5). Geometric mean PRNT60
titers against wild-type DENV-1 following the second dose of
vaccine were similar in cohorts 1 and 2 (Table 5). Three of the
four subjects who did not seroconvert after the first dose of vaccine
received a second dose of vaccine four months later; none of them
developed a $4-fold rise in serum neutralizing antibody titer or in
ELISA antibody titer. Of the subjects who seroconverted to
DENV-1 after the first vaccination, one who received a second
dose of vaccine four months after the first dose developed a $4-
fold rise in ELISA antibody titer following the second dose, as did
four subjects who received a second dose six months after the first
dose (Table 5). These findings suggest that a single dose of
rDEN1D30 was highly infectious and was able to provide
sterilizing humoral immunity to infection with the vaccine virus
for at least 6 months in 83% of vaccinees.
Discussion
The development of a safe and effective tetravalent dengue
vaccine has been a goal for decades, yet a licensed vaccine is still not
available. At a minimum, such a vaccine must have an acceptable
safety profile and must induce long-lived protective immunity
against all four serotypes of wild type dengue virus. Ideally this
would be accomplished with a single dose of vaccine. However,
tetravalent vaccines currently in clinical development require two or
three doses [14,18]. A number of dengue viruses have been atte-
nuated either by serial passage in tissue culture or by the intro-
duction of attenuating mutations and/or chimerization of dengue
viruses using recombinant DNA technology [26,29,30,31,32]. In
addition, a tetravalent vaccine based on chimerization of DENV-1-
4 with the yellow fever vaccine virus is currently in Phase II/III
clinical development [14,20]. Other investigational vaccines have
been abandoned because they were either under or over-attenuated
[15,16,17,33,34]. In addition, there are concerns that viral
interference may affect the ability of a live attenuated tetravalent
dengue vaccine to induce a balanced immune response to all four
serotypes. For these reasons, we have attempted to carefully
examine the safety profile and humoral immune response to each
monovalent DENV vaccine candidate virus prior to formulating a
tetravalent vaccine. Clinical examination and laboratory studies
performed every other day for the first 16 days post vaccination
have helped to fully characterize the reactogenicity and kinetics of
replication of these viruses when given as monovalent vaccines.
The ability of live attenuated dengue vaccines to induce a
satisfactory antibody response without clinically significant reacto-
genicity has been a hurdle to DENV vaccine development. There
are few published studies of monovalent DENV-1 vaccines to which
we can compare the safety and immunogenicity of rDEN1D30 in
healthy adult subjects. Three such studies describe the DENV-1
vaccine candidates 16007, 45AZ5 PDK20, and 45AZ5 PDK27
[17,35,36]. These candidates were attenuated by serial passage in
tissue culture, and the parent virus of 45AZ5 PDK20 and 45AZ5
PDK27 underwent chemical mutagenesis prior to passage in tissue
culture. Five subjects received DENV-1 16007 as a monovalent
vaccineand12subjectsreceived45AZ5PDK20.Vaccinecandidate
16007 was well tolerated: none of the subjects developed an oral
Table 3. Viremia onset, duration, and mean peak titer following a first dose of rDEN1D30.
rDEN1D30 Lot #
Cohort and
dosing schedule Dose N
No (%)
infected
1
No (%) with
viremia
Mean peak titer
±SE (log10 PFU/mL)
2
Mean day
of onset of
viremia ±SE
Mean # of days
of viremia ±SE
DEN1#1
3 Single dose 1 20 19 (95) 9 (45) 1.060.2 9.860.7 2.860.8
DEN1#104A Cohort 1, 0+120 1 26 23 (88) 17 (65) 1.160.1 10.160.5 3.460.5
DEN1#104A Cohort 2, 0+180 1 25 25 (100) 17 (68) 1.060.2 10.860.7 3.660.5
Aggregate data for all subjects: 71 67 (94) 43 (61) 1.060.1 10.360.4 3.360.3
1Infected is defined as recovery of vaccine virus from the blood and/or a $4-fold rise in PRNT60 by day 42 post vaccination compared with day 0.
2Mean peak titer is calculated for viremic subjects only.
3Historical Data [28].
doi:10.1371/journal.pntd.0001267.t003
Table 4. Serum neutralizing antibody response induced by a single 10
3 PFU dose of rDEN1D30.
rDEN1D30 Lot #
Cohort and dosing
schedule N % infected
2 (%)
Reciprocal geometric mean PRNT60
(range)
1 % seroconversion by
PRNT
3
Day 0 Day 42
DEN1#1
4 Single dose 20 95 ,5 181 (8–1242) 95
DEN1#104A Cohort 1, 0+120 25 88 ,5 106 (,5–527) 84
DEN1#104A Cohort 2, 0+180 25 100 ,5 169 (7–965) 100
Aggregate data 70 94 - 142 (,5–1242) 93
1Plaque reduction neutralization titer 60%. Geometric mean titers calculated for all subjects who developed detectable antibody, including those who did not
seroconvert (see footnote 3).
2Infection is defined as recovery of vaccine virus from the blood and/or seroconversion to DEN1.
3Seroconversion is defined as a $4-fold rise in PRNT60 at day 28 or 42 post-vaccination.
4Previous trial. All serum samples from the current and previous trial were re-assayed concurrently.
doi:10.1371/journal.pntd.0001267.t004
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developed elevated liver function tests [35]. However, only 60% of
vaccinees seroconverted to the vaccine as defined as a PRNT50
$1:10.In contrast, 100% of vaccinees seroconverted to DEN1 after
receipt of the monovalent DENV-1 vaccine 45AZ5 PDK20;
however, 5/12 subjects developed a temperature .38uC and 3/
12 developed dengue-like illness [17]. Additionally, 20% to 35% of
subjects who received a tetravalent formulation containing 45AZ5
PDK20 developed a temperature of .38uC [18]. The further
passaged DENV-1 candidate vaccine 45AZ5 PDK27 was evaluated
as a monovalent DENV-1 vaccine in 10 subjects and was found to
be more attenuated than 45AZ5 PDK20 [36]. While the
reactogenicity profile of 45AZ5 PDK27 was acceptable, only 40%
of vaccinees seroconverted to DENV-1 following a single dose of
45AZ5 PDK27 [36]. Although 45AZ5 PDK27 was less immuno-
genic than 45AZ5 PDK20, it has replaced 45AZ5 PDK27 in the
tetravalent formulations currently under evaluation, illustrating the
trade-off that is sometimes necessary to balance reactogenicity and
immunogenicity. Thus, achieving a satisfactory balance between
attenuation and immunogenicity has been difficult to attain by
passageand/ormutagenesisofDENV-1.IntherDEN1D30vaccine
virus, the attenuating 30 nucleotide deletion is located in the 39
UTR but the virus is otherwise wild-type. This might have
contributed to its high level of infectivity and immunogenicity.
The promising safety profile of the rDEN1D30 vaccine described
in a previous single-dose study was affirmed in the current two-dose
study [22]. None of the subjects developed fever, a dengue-like illness
or any study-related SAE. All of the clinical solicited adverse events
were mild or moderate in severity and were transient in nature. As we
have reported for our previous dengue vaccine studies, neutropenia
andrashwerethemostcommonlyreportedadverseeventsinsubjects
who received rDEN1D30. As was seen in the previous study of this
vaccine candidate, the onset of neutropenia and rash generally
followed the onset of viremia. The definition of neutropenia used in
our studies is more inclusive than that utilized in many other dengue
vaccine studies. We defined neutropenia as an ANC of #1500/mm
3
and obtained blood counts every other day for the first 16 days after
vaccination; other studies of leading dengue vaccine candidates have
defined neutropenia as an ANC,1,000/mm
3 with less frequent
monitoring, e.g. only on day 15, or on days 4, 8, 12, and 16 post
vaccination [14,17,18,20]. Had we used an ANC,1,000/mm
3 to
define neutropenia our studies, only 2/71 (ANC measured on day 16
o n l y )o r5 / 7 1( A N Cm e a s u r e do nd a y s4 ,8 ,1 2 ,a n d1 6o n l y )v a c c i n e
recipients would have been described as neutropenic, a rate of
neutropenia comparable to that reported in the studies indicated
above. In addition, more than 60% of our study subjects were of
African descent, a population known to maintain a lower mean
baseline ANC [37,38,39]. In comparison, subjects of African descent
made up only 5–33% of volunteers in the studies referenced above.
Most importantly, the very short duration of neutropenia observed in
recipients of rDEN1D30 was not associated with fever or other
clinical signs or symptomssuggestive of neutropenia-related illness. In
contrast to neutropenia associated with neoplasia or therapeutic
interventions, we assume that neutrophil function during DENV
infection or following vaccination with a live-attenuated DENV
vaccine is not compromised and that the short duration of
neutropenia does not compromise protective immune functions.
Our monovalent DENV vaccines have been evaluated in approx-
imately 500 subjects thus far and fever of unknown origin or any sign
or symptom suggestive of opportunistic infections has not been
observed. To our knowledge, neutropenia due to natural dengue
illness has not been associated with secondary bacteremia. A review
of cases of concomitant bacteremia in patients diagnosed with DHF
found that leukopenia was not associated with an increased incidence
of bacteremia compared with control patients [40].
The investigational vaccine rDEN1D30 appears to have a well-
balanced safety and immunogenicity profile. In addition to the
acceptable reactogenicity of rDEN1D30 described above, the
vaccine was able to induce an overall seroconversion rate of 93%
(65/70 subjects) when administered as a single subcutaneous dose
to flavivirus-naı ¨ve healthy adults. Importantly, the immunogenic-
ity end-point used in both this and our previously reported study of
rDEN1D30 was a 4-fold rise in serum neutralizing antibody (i.e., a
PRNT60 titer of $1:20 defined seroconversion) and is more
stringent compared with a PRNT50 titer of $1:10 used by others
in the studies described above. In addition to the high
seroconversion rate that was achieved following a single dose of
vaccine, rDEN1D30 induced sterilizing humoral immunity to
infection with a second dose of vaccine administered 4 or 6 months
later in the vast majority of vaccinees, a finding that could be
indicative of long-term homotypic protection as has been
described following natural DENV infection [10,41].
In the present study, the four subjects who did not develop
detectable neutralizing antibody after the first dose of rDEN1D30
could not be infected by a second dose of vaccine given 4 months
later. Following dose 1, one of the 4 subjects had laboratory
findings consistent with infection by the vaccine virus, and another
subject had findings that may be suggestive of infection by the
vaccine virus. The former had detectable viremia on study day 12
and a mild neutropenia on study day 16, and the latter subject was
mildly neutropenic on study day 4 following first vaccination. The
other two subjects did not have clinical or laboratory findings
suggestive of infection. Of these four subjects, three received a
second dose of vaccine but did not develop a detectable
Table 5. Serum antibody response induced by a second 10
3 PFU dose of rDEN1D30 given at 4 or 6 months after first dose.
rDEN1D30 Lot#
Cohort and dosing
schedule N % infected
1 Reciprocal geometric mean PRNT60 (range)
1 % Boosted by
PRNT
5
No (%) with $4-
fold rise in ELISA
titer
Day 0
2 Day 28
3 Day 42
4
DEN1#104A Cohort 1,(0+120) 22 0 39 (,5–300) 38 (,5–284) 36 (,5–176) 0
5 1 (5)
DEN1#104A Cohort 2, (0+180) 23 0 37 (,5–361) 36 (5–284) 31 (,5–180) 0
5 4 (17)
1Infection is defined as recovery of vaccine virus from the blood and/or seroconversion to DEN1 by PRNT60.
2Day 0 is day of second vaccination (day 120 for 0/120 cohort and day 180 for 0/180 cohort).
3Day 28 is day 28 post-second vaccination.
4Day 42 is day 42 post-second vaccination
5Boost is defined as a $4-fold rise in PRNT60 at day 28 or 42 post-vaccination.
doi:10.1371/journal.pntd.0001267.t005
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whether these individuals were vaccine non-responders, complete-
ly resistant to infection, or whether their innate immune system
was able to abort infection prior to the induction of an antibody
response. Loss of vaccine potency was excluded as a cause for the
absence of infection following dose 2.
This study has important implications for the development of a
live attenuated tetravalent dengue vaccine. First, the expanded
safety evaluation of the monovalent rDEN1D30 vaccine confirmed
it to be well tolerated without vaccine-related fever or dengue-like
illness. Second, the vaccine was able to induce seroconversion to
DENV-1 in 93% of recipients when given as a single subcutaneous
dose of 10
3 PFU. The 10
3 PFU dose required for the induction of
seroconversion to DENV-1 and the ability to grow this virus to high
titer (.10
7 PFU/mL), make this a very economical vaccine
component to produce. Third, the vaccine virus behaved
immunologically much like wild-type virus in that sterilizing
homotypic immunity was induced after a single dose. It is unknown
whether this will make boosting of the humoral response to DENV-
1 more difficult should multiple doses of the tetravalent vaccine be
required. It is also not known whether the observed protection
against a second dose of vaccine virus will translate into protection
against infection/disease following exposure to wild type DENV-1
virus after vaccination. Future studies with tetravalent vaccine will
need to evaluate whether boosting is necessary and will need to be
designed to determine a suitable interval for boosting. Lastly,
because the replication kinetics of this virus have been very well
characterized as a monovalent vaccine, any effect of viral
interference on the replication kinetics of the vaccine when
administered as part of a tetravalent formulation should be
discernable. In summary, rDEN1D30 is an excellent candidate for
inclusion in live tetravalent dengue vaccine formulations, and
clinical evaluation of tetravalent dengue vaccines with this
rDEN1D30 as DENV-1 component have been initiated.
Our study has at least two potential limitations regarding the
infectivity, safety, and immunogenicity of rDEN1D30 when
administered as a component of a tetravalent formulation. First,
sterilizing humoral immunity to a second dose of monovalent
rDEN1D30 vaccine at 6 months might not translate into sterilizing
humoral immunity six months after vaccination with a tetravalent
vaccine. It is not known whether or not the high seroconversion
rates achieved following a single dose of the rDEN1D30 vaccine,
when given as a monovalent virus, will be achievable when the
candidate vaccine is included in a tetravalent formulation.
Secondly, the results of our studies in flavivirus-naive healthy
adults do not necessarily mirror how this investigational vaccine
will behave in flavivirus-naive and partially immune children, one
of the target groups for vaccination in several hyperendemic areas.
Tetravalent vaccine studies will need to carefully proceed from
adults into children and from flavivirus-naive into partially
immune individuals to evaluate the safety and immunogenicity
of this vaccine in these vulnerable populations.
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